A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

Explore our latest breakthroughs in RNA Interference Research. Learn more about our innovative pipeline today! @ RNA ...

Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) ...

In a world first, researchers have mapped the cellular dynamics following treatment with the most commonly used advanced ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Colossal, the company founded to try to restore the mammoth to the Arctic tundra, has also decided to tackle a number of ...

The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients ...

The researchers analyzed CD4 T cell and B cell responses 7 days and 3–6 months after two doses of the SARS-CoV-2 messenger ...

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapyPatent applications for the ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity's stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Au ...